{"title":"larorectinib在NTRK3融合阳性乳腺转移性分泌性癌中的应用：一个病例研究","authors":"Martin Dietrich , Michel Velez","doi":"10.1016/j.cpccr.2024.100334","DOIUrl":null,"url":null,"abstract":"<div><div>Triple-negative breast cancer (TNBC) is an aggressive heterogeneous form of breast cancer that accounts for 15 %-20 % of all breast cancers. Characterized by an absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, TNBCs are often treated with surgery, chemotherapy, radiation, and, most recently, with immunotherapy; however, patients with treatment-resistant TNBC often relapse and have an extremely poor prognosis. Here we present a case of recurrent metastatic TNBC responsive to the TRK inhibitor larotrectinib.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100334"},"PeriodicalIF":0.2000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Larotrectinib in NTRK3 fusion–positive metastatic secretory carcinoma of the breast: A case study\",\"authors\":\"Martin Dietrich , Michel Velez\",\"doi\":\"10.1016/j.cpccr.2024.100334\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Triple-negative breast cancer (TNBC) is an aggressive heterogeneous form of breast cancer that accounts for 15 %-20 % of all breast cancers. Characterized by an absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, TNBCs are often treated with surgery, chemotherapy, radiation, and, most recently, with immunotherapy; however, patients with treatment-resistant TNBC often relapse and have an extremely poor prognosis. Here we present a case of recurrent metastatic TNBC responsive to the TRK inhibitor larotrectinib.</div></div>\",\"PeriodicalId\":72741,\"journal\":{\"name\":\"Current problems in cancer. Case reports\",\"volume\":\"17 \",\"pages\":\"Article 100334\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current problems in cancer. Case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666621924000565\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621924000565","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Larotrectinib in NTRK3 fusion–positive metastatic secretory carcinoma of the breast: A case study
Triple-negative breast cancer (TNBC) is an aggressive heterogeneous form of breast cancer that accounts for 15 %-20 % of all breast cancers. Characterized by an absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, TNBCs are often treated with surgery, chemotherapy, radiation, and, most recently, with immunotherapy; however, patients with treatment-resistant TNBC often relapse and have an extremely poor prognosis. Here we present a case of recurrent metastatic TNBC responsive to the TRK inhibitor larotrectinib.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
